A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer

A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer

Background: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have poor 5-year survival. Pharmacological ascorbate (P-AscH-, high dose, intravenous, vitamin C) has shown promise as an adjunct to chemotherapy. We hypothesized adding P-AscH- to gemcitabine and nab-paclitaxel would incre...

Full description

Bibliographic Details
Main Authors: Kellie L. Bodeker, Brian J. Smith, Daniel J. Berg, Chandrikha Chandrasekharan, Saima Sharif, Naomi Fei, Sandy Vollstedt, Heather Brown, Meghan Chandler, Amanda Lorack, Stacy McMichael, Jared Wulfekuhle, Brett A. Wagner, Garry R. Buettner, Bryan G. Allen, Joseph M. Caster, Barbara Dion, Mandana Kamgar, John M. Buatti, Joseph J. Cullen
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Redox Biology
Subjects:
Pancreatic neoplasms
Ascorbic acid
Controlled clinical trial
Gemcitabine
Nab-paclitaxel
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231724003537

Internet

http://www.sciencedirect.com/science/article/pii/S2213231724003537

Similar Items